VENTYX BIOSCIENCES INC. - COMMON STOCK

Ventyx Biosciences Provides Update on Silicon Valley Bank Financial Exposure

11 مارس 2023 13:21:31 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

28 فبراير 2023 08:00:03 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences Announces Pipeline Updates and Highlights Strategic Priorities at Investor R&D Day

26 يناير 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences Appoints Allison J. Hulme, Ph.D. and Onaiza Cadoret-Manier to its Board of Directors

12 يناير 2023 08:00:00 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences to Host R&D Event on January 26, 2023

05 يناير 2023 08:00:01 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences Announces Dosing of the First Patient in the Phase 2 SERENITY Trial of VTX958 for the Treatment of Moderate to Severe Plaque Psoriasis

01 ديسمبر 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

22 نوفمبر 2022 08:00:02 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences Reports Third Quarter 2022 Financial Results and Highlights Recent Corporate Progress

03 نوفمبر 2022 16:01:01 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences to Report Third Quarter 2022 Financial Results on November 3, 2022

27 أكتوبر 2022 16:05:01 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

27 أكتوبر 2022 09:00:01 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences Announces $176.6 Million Private Placement of Common Stock

19 سبتمبر 2022 08:00:00 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

29 أغسطس 2022 16:05:00 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences Reports Second Quarter 2022 Financial Results and Highlights Recent Corporate Progress

15 أغسطس 2022 16:05:01 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences Announces Positive Topline Phase 1 Data for Its Selective Allosteric TYK2 Inhibitor VTX958

15 أغسطس 2022 16:01:00 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences to Report Topline Results from the Phase 1 trial of its TYK 2 Inhibitor VTX958 and Second Quarter 2022 Financial Results on August 15, 2022

11 أغسطس 2022 16:05:03 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences Announces Positive Topline Phase 1 Data for its Peripheral NLRP3 Inhibitor VTX2735

29 يونيو 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences to Participate in the Jefferies Healthcare Conference

01 يونيو 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences Reports First Quarter 2022 Financial Results and Highlights Recent Corporate Progress

12 مايو 2022 16:01:00 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences Announces Appointment of William Sandborn, MD, as President and Chief Medical Officer

09 مايو 2022 08:00:01 بحسب Nasdaq GlobeNewswire

Ventyx Biosciences to Report First Quarter 2022 Financial Results on May 12, 2022

05 مايو 2022 16:05:01 بحسب Nasdaq GlobeNewswire